The Prevalence of Factor XII Deficiency in 103 Orally Anticoagulated Outpatients Suffering from Recurrent Venous and/or Arterial Thromboembolism

Summary

One hundred and three patients suffering from recurrent venous thrombosis, recurrent arterial thromboembolism and/or recurrent myocardial infarction and 50 healthy subjects were tested for Hageman factor (FXII) coagulant activity and antigen. Among the 103 patients we identified 15 subjects with FXII deficiency (15%), 3 with protein C deficiency (3%) and 3 with protein S deficiency (3%). Combined FXII and protein C, protein S or antithrombin III deficiency was not observed. The 103 patients were devided into subgroups according to the type of thrombotic complication. Among patients with exclusively recurrent venous thromboembolism 8% (p = 0.153) were deficient in FXII. Among patients suffering from recurrent arterial thromboembolism and/or myocardial infarction, the incidence of FXII deficiency was significantly higher (20%, p < 0.003). In 67% of the patients with FXII deficiency a positive family history of thrombosis could be established. In contrast, only 32% of all venous and 28% of all arterial thrombosis patients had a positive family history. We believe that reduced levels of FXII should be considered as a risk factor in the development of thromboembolism. Consequently, more attention should be payed to the measurement of FXII when evaluating thromboembolic risk factors especially in cases of recurrent arterial thromboembolism and/or myocardial infarction.

• References

• 1 Schmaier AH, Silverberg M, Kaplan AP, Colman RW. Contact activation and its abnormalities. Haemostasis and Thrombosis. 2^nd edn Colman RW, Hirsh J, Marder VJ, Salzman EW. Lippincott Company, Philadelphia, PA: 1987: 18-38
• 2 Kluft C, Dooijewaard G, Emeis JJ. Role of the contact system in fibrinolysis. Semin Thromb Hemostas 1987; 13: 50-68
• 3 Ratnoff OD, Busse RJ, Sheron RP. The demise of John Hageman. New Engl J Med 1968; 279: 420-423
• 4 Goodnough LT, Saito H, Ratnoff OD. Thrombosis or myocardial infarction in congenital clotting factors abnormalities and chronic thrombocytopenias: A report of 21 patients and a review of 50 previously reported cases. Medicine 1983; 62: 248-255
• 5 Mannhalter C, Fischer M, Hopmeier P, Deutsch E. Factor XII activity and antigen concentrations in patients suffering from recurrent thrombosis. Fibrinolysis 1987; 1: 259-263
• 6 Lämmle B, Wuillemin WA, Huber I, Krauskopf M, Zürcher C, Pflugshaupt R, Furlan M. Thromboembolism and bleeding tendency in congenital factor XII deficiency – A study on 74 subjects from 14 Swiss families. Thromb Haemostas 1991; 65: 117-121
• 7 Penny WJ, Colvin BT, Brooks N. Myocardial infarction with normal coronary arteries and factor XII deficiency. Br Heart J 1985; 53 (2) 230-234
• 8 Lodi S, Isa L, Pollini E, Bravo AF, Scalvini A. Defective intrinsic fibrinolytic activity in a patient with severe factor XII-deficiency and myocardial infarction. Scand J Haematol 1984; 33 (1) 80-2
• 9 Lodino Jr AV, Luparello FJ. Factor XII deficiency in a man with gout and angioimmunoblastic lymphadenopathy. Arch Intern Med 1984; 144 (7) 1497-1498
• 10 Hoak JC, Swanson LW, Warner ED, Connor WE. Myocardial infarction associated with severe factor-XII deficiency. Lancet 1966; ii (469) 884-886
• 11 Glueck HI, Roehill Jr W. Myocardial infarction in a patient with Hageman (factor XII) defect. Ann Intern Med 1966; 64 (2) 390-396
• 12 Hellstern P, Koehler M, Schmengler K, Doenecke P, Wenzel E. Arterial and venous thrombosis and normal response to streptokinase treatment in a young patient with severe Hageman factor deficiency. Acta Haematol 1983; 69 (2) 123-126
• 13 Thommen D, Buhrfeind E, Felix R, Sulzer I, Furlahn M, Lämmle B. Hämostaseparameter bei 55 Patienten mit venösen und/oder arteriellen Thromboembolien. Schweiz Med Wschr 1989; 119: 493-499
• 14 Ferrer MI, Bradley SE, Bull MB, Dolgin M, Ellis K, Enson Y, Escher DJW. et al The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. Little, Brown and Company, Boston, MA: 1989: 119 pp
• 15 Ratnoff OD, Saito H. The evolution of clot-promoting and amidolytic activities in mixtures of Hageman factor (factor XII) and ellagic acid. J Lab Clin Med 1982; 100: 248-260
• 16 Rosner E, Pauzner R, Lusky A, Modan M, Many A. Detection and quantitative evaluation of lupus circulating anticoagulant activity. Thromb Haemostas 1987; 57: 144-147
• 17 Laurell CB. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966; 15: 45-52
• 18 Passing H, Bablok W. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry. J Clin Chem Clin Biochem 1983; 21: 709-720
• 19 Simpson GG, Roe A, Lewontin RC. Quantitative Zoology. Harcourt, Brace & World Inc: New York: 1960. pp 189-191
• 20 Rijken DC, Wijngaards G, Welbergen J. Relationship between tissue plasminogen activator and the activators in blood and vascular wall. Thromb Res 1980; 18: 815-830
• 21 Kluft C, Trumpi-Kalshoven MM, Jie AFH, Veldhuyzen-Stolk EC. Factor XII-dependent fibrinolysis: a double function of plasma kallikrein and the occurrence of a previously undescribed factor XII- and kallikrein-dependent plasminogen proactivator. Thromb Haemostas 1979; 41: 756-773
• 22 Binnema DJ, Dooijewaard G, van Iersel JJL, Turion PNC, Kluft C. The contact-system dependent plasminogen activator from human plasma: identification and characterization. Thromb Haemostas 1990; 64: 390-397
• 23 Levi M, Hack CE, de Boer JP, Brandjes DPM, Büller HR, ten Cate JW. Reduction of contact activation related fibrinolytic activity in factor XII deficient patients. J Clin Invest 1991; 88: 1155-1160
• 24 Brauer P, Mayer J, Pohl B, Zürrlein P, Keller F. Specificity of confirmatory tests for the diagnosis of a lupus anticoagulant I: mixing studies of the kaolin clotting time. Ann Hematol (Contin Blut), 35^th Annual Meeting of the GTH, Göttingen 1991; A70: 137
• 25 Ben-Tal O, Zivelin A, Seligson U. The relative frequency of hereditary thrombotic disorders among 107 patients with thrombophilia in Israel. Thromb Haemostas 1989; 61 (1) 50-54
• 26 Heijboer H, Brandjes DPM, Büller HR, Sturk A, ten Cate JW. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 1990; 323: 1512-1516
• 27 Duckert F. Beeinflussung der Blutgerinnung durch den Diabetes mellitus. Blutgerinnung und Pankreas Tilsner V, Matthias FR. Editiones Roche, Basel: 1986: 155-62
• 28 Christe M, Gattlen P, Fritschi J, Lämmle B, Berger W, Marbet GA, Duckert F. The contact phase of blood coagulation in diabetes mellitus and in patients with vasculopathy. Thromb Haemostas 1984; 52: 221-223